anthrax vaccine

Latest Headlines

Latest Headlines

BARDA continues support of pre- and post-exposure Anthrax vax

Intramuscular injection of an anthrax prophylactic has sustained the attention of the U.S. Biomedical Advanced Research & Development Authority (BARDA) to the tune of $68 million. New

U.S. increases Emergent BioSolutions' anthrax vax contract

Emergent BioSolutions is adding another 3.42 million doses to its 14.5 million-dose BioThrax contract with the U.S. government. The contract extension is worth an approximate $101 million; the

Combo anthrax/smallpox vax beats anthrax vax alone

Researchers have found that combination vaccines that protect against multiple maladies work better than vaccines for individual infections, including anthrax vaccines stockpiled by the U.S.

NIAID awards $46.3 million in vax grants and contracts

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two grants to vaccine makers for anthrax and hepatitis B vaccines, respectively. Emergent BioSolutions received a

Project BioShield's vax programs on the chopping block

When Congress created Project BioShield four years ago, lawmakers believed that offering developers contracts guaranteeing the acquisition of new vaccines and drugs would spur the biotech industry to

iBio tech to be used for anthrax, plague vax

iBio has confirmed that its proprietary technology, the iBioLaunch platform, will help support a $5.3 million government-funded project for the development of a single vaccine to protect against both

Feds' anthrax shift triggers sharp drop in developers' shares

The U.S. Department of Health and Human Services has decided to drop a request for proposals for a next-gen recombinant protective antigen anthrax vaccine, saying the agency doesn't believe that

HGS hit with anthrax setback

In a setback for Human Genome Sciences, the FDA said that questions regarding the human data collected on its anthrax drug made it impossible "to make a complete judgment about whether raxibacumab

FDA approves sBLA for BioThrax

The FDA has approved Emergent BioSolution's sBLA for BioThrax, the company's anthrax vaccine. The new approval changes the number of total vaccinnations that must be administered. It now calls for

Emergent wins $404M anthrax vax contract

Emergent BioSolutions' monopoly on approved anthrax vaccines was worth a new federal contract worth up to $404 million for a fresh stockpile. Emergent will supply 14.5 million doses of its vaccine